Description: OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898 and OBI-998 drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
Home Page: www.obipharma.com
No. 3, Park Street
Taipei,
115
Taiwan
Phone:
886 2 2655 8799
Officers
| Name | Title |
|---|---|
| Dr. Michael N. Chang PH.D. | CEO & Chairman |
| Mr. Chi-Chuan Chen | CFO & Director |
| Dr. Ming-Tien Lai | Chief Scientific Officer |
| Dr. Yun Yen F.A.C.P., FACP, M.D., Ph.D. | Exec. VP & Director |
| Mr. Po-Jen Chang | Director of HR & Admin. |
| Ms. Sharon Lee | Director of PR |
| Mr. Kevin P. Poulos | Chief Bus. Officer of USA |
| Mr. Mitchell Che M.S. | Chief Operating Officer of USA |
| Dr. Wayne Saville M.D. | Chief Medical Officer |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3265 |
| Price-to-Sales TTM: | 2516.5867 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |